These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 23872668)

  • 1. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
    Duijvestein M; Vos AC; Roelofs H; Wildenberg ME; Wendrich BB; Verspaget HW; Kooy-Winkelaar EM; Koning F; Zwaginga JJ; Fidder HH; Verhaar AP; Fibbe WE; van den Brink GR; Hommes DW
    Gut; 2010 Dec; 59(12):1662-9. PubMed ID: 20921206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study.
    Jauregui-Amezaga A; Cabezón R; Ramírez-Morros A; España C; Rimola J; Bru C; Pinó-Donnay S; Gallego M; Masamunt MC; Ordás I; Lozano M; Cid J; Panés J; Benítez-Ribas D; Ricart E
    J Crohns Colitis; 2015 Dec; 9(12):1071-8. PubMed ID: 26303633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.
    Cassinotti A; Annaloro C; Ardizzone S; Onida F; Della Volpe A; Clerici M; Usardi P; Greco S; Maconi G; Porro GB; Deliliers GL
    Gut; 2008 Feb; 57(2):211-7. PubMed ID: 17895357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saccharomyces boulardii does not prevent relapse of Crohn's disease.
    Bourreille A; Cadiot G; Le Dreau G; Laharie D; Beaugerie L; Dupas JL; Marteau P; Rampal P; Moyse D; Saleh A; Le Guern ME; Galmiche JP;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):982-7. PubMed ID: 23466709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC; Gerlier L; Brabant Y; Brown M
    Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease.
    Gibson PR; Weston AR; Shann A; Florin TH; Lawrance IC; Macrae FA; Radford-Smith G
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1306-12. PubMed ID: 17559375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trichuris suis therapy in Crohn's disease.
    Summers RW; Elliott DE; Urban JF; Thompson R; Weinstock JV
    Gut; 2005 Jan; 54(1):87-90. PubMed ID: 15591509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cells as treatment in inflammatory bowel disease.
    Hawkey CJ
    Dig Dis; 2012; 30 Suppl 3():134-9. PubMed ID: 23295704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sargramostim for active Crohn's disease.
    Korzenik JR; Dieckgraefe BK; Valentine JF; Hausman DF; Gilbert MJ;
    N Engl J Med; 2005 May; 352(21):2193-201. PubMed ID: 15917384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.